BRÈVE

sur NOVACYT (EPA:ALNOV)

Novacyt announces the financial impacts of the agreement with DHSC

Graphique de l'évolution du cours de l'action NOVACYT (EPA:ALNOV).

Clinical diagnostics specialist Novacyt has announced a financial update following its agreement with the UK Department of Health and Social Care (DHSC). The company could see a net increase in its cash flow of around £7 million due to the VAT recovery.

The agreement, dated June 11, 2024, requires Novacyt to pay £5 million to DHSC. The unpaid £20 million bill from December 2020 will be written off as a bad debt. The product warranty provision of £19.8 million will be cancelled. The settlement costs of £5 million will be recognized as exceptional items.

Novacyt has requested a refund of £12.2 million in VAT paid to HMRC. If this request is granted, net cash flow will increase by £7 million. Details will be discussed at the Annual General Meeting on July 18, 2024.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de NOVACYT